Biomaterial Database

Endocrine therapy in pancreatic carcinoma. 1998

J Yamashita, and M Abe, and M Ogawa

Department of Surgery II, Kumamoto University School of Medicine, Kumamoto, Japan.

There are indications of the possible effects of sex hormones on pancreatic carcinoma. Estrogen receptor (ER) has been demonstrated in pancreatic tumors in experimental animals and in humans and it has been suggested that endocrine manipulation may be effective in the treatment of pancreatic carcinoma. However, it is still controversial whether this lethal cancer can potentially benefit from endocrine therapy. One explanation for the conflicting data on the benefit of hormonal manipulation in the treatment of pancreatic carcinoma may stem from the fact that there is no adequate marker to assess estrogen dependency of the pancreatic tumors. In this article, we review our work on tissue plasminogen activator as a prognostic guide to evaluate the efficacy of hormonal therapy in human pancreatic carcinoma, and also suggest that a selected subgroup of patients with this lethal cancer may have a potential clinical benefit from endocrine therapy, especially medroxyprogesterone acetate treatment.

UI	MeSH Term	Description	Entries
D009376	Neoplasms, Hormone-Dependent	Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.	Hormone-Dependent Neoplasms,Hormone Dependent Neoplasms,Hormone-Dependent Neoplasm,Neoplasm, Hormone-Dependent,Neoplasms, Hormone Dependent
D010190	Pancreatic Neoplasms	Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D010959	Tissue Plasminogen Activator	A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.	Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D004965	Estrogen Antagonists	Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.	Estradiol Antagonists,Antagonists, Estradiol,Antagonists, Estrogen
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017258	Medroxyprogesterone Acetate	A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.	Depo-Medroxyprogesterone Acetate,Medroxyprogesterone 17-Acetate,Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6alpha)-,(6 alpha)-17-(Acetoxy)-6-methylpregn-4-ene-3,20-dione,6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate,Curretab,Cycrin,Depo-Provera,Farlutal,Gestapuran,Medroxyprogesterone 17-Acetate, (6 alpha,17 alpha)-Isomer,Medroxyprogesterone 17-Acetate, (6 beta)-Isomer,Perlutex,Provera,Veramix,6 alpha Methyl 17alpha hydroxyprogesterone Acetate,Depo Medroxyprogesterone Acetate,Depo Provera,DepoProvera,Medroxyprogesterone 17 Acetate
D018931	Antineoplastic Agents, Hormonal	Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)	Hormonal Antineoplastic Agents,Antineoplastic Drugs, Hormonal,Antineoplastic Hormonal Agents,Antineoplastic Hormonal Drugs,Antineoplastics, Hormonal,Hormonal Agents, Antineoplastic,Hormonal Antineoplastic Drugs,Hormonal Antineoplastics,Agents, Antineoplastic Hormonal,Drugs, Antineoplastic Hormonal,Hormonal Drugs, Antineoplastic

Related Publications

J Yamashita, and M Abe, and M Ogawa

Endocrine pancreatic carcinoma.

April 1991, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,

J Yamashita, and M Abe, and M Ogawa

Mixed exocrine-endocrine pancreatic carcinoma in childhood.

January 2005, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology,

J Yamashita, and M Abe, and M Ogawa

[Liver metastases of pancreatic endocrine carcinoma].

April 2010, Medicina clinica,

J Yamashita, and M Abe, and M Ogawa

Gastric carcinoma resembling pancreatic mixed acinar-endocrine carcinoma.

May 2002, Human pathology,

J Yamashita, and M Abe, and M Ogawa

[Endocrine therapy in breast carcinoma].

September 1988, Minerva chirurgica,